HSG Blog

Highly Cited HD Research

In this edition of HD Insights, we take a look at impactful HD research articles of 2015. We searched Thomson...

Research Round-Up

Research Round-Up

By: Lise Munsie, PhD In pharma… The well-tolerated, FDA-approved drug metformin is an antidiabetic drug that mimics caloric restriction. Jin...

MEET THE COMPANY: uniQure

VITAL SIGNS NAME: uniQure STOCK SYMBOL: QURE    SHARE PRICE AS OF 2/17/17: $6.31 52-WEEEK RANGE AS OF 2/17/17: $5.25-$16.40...

MEET THE SCIENTIST: Pavlina Konstantinova, MSc, PhD

MEET THE SCIENTIST: Pavlina Konstantinova, MSc, PhD

VITAL SIGNS NAME: Pavlina Konstantinova, MSc, PhD TITLE: Director of Emerging Technologies and Huntington Disease Program Leader, uniQure EDUCATION: MSc,...

MEET THE COMPOUND: AMT-130

MEET THE COMPOUND: AMT-130

By: Meredith A. Achey, BM MANUFACTURER: uniQure COMPOUND: Artificial micro RNA targeting human huntingtin, carried by an adeno-associated virus 5...

Highlights from the Journal of HD

Assistive technology for cognition in HD By: Marleen R. van Walsem, MSc, Emilie I. Howe, MSc and Jan C. Frich,...

Thank you to Teva Pharmaceuticals

HD Insights thanks Teva for its ongoing support Teva CNS is committed to continued research and development of its product portfolio...

Highlights of HSG 2016: Discovering Our Future

The Huntington Study Group held its 23rd Annual Meeting and 10th Annual Clinical Research Symposium November 2-5, in Nashville, TN....

Thank you to Raptor

Thank you to Raptor

HD Insights thanks raptor for its generous support.

Editor’s Letter

Welcome to the 16th edition of HD Insights, timed for release at the beginning of the first Pan-American Parkinson’s Disease...

1 3 4 5 6 7 22